Research programme: SeV-based gene therapies - ID Pharma

Drug Profile

Research programme: SeV-based gene therapies - ID Pharma

Alternative Names: SeV 10102; SeV 10401; SeV 10501; SeV 20201; SeV 20202; SeV 20301; SeV 20302; SeV2 0401

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DNAVEC Corporation
  • Class Gene therapies; Nucleic acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Cystic fibrosis; Ischaemic heart disorders

Highest Development Phases

  • No development reported Alzheimer's disease; Brain cancer; Coronavirus infections; Cystic fibrosis; HIV-1 infections; Ischaemic heart disorders; Malignant melanoma; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Brain-cancer in Japan
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cystic-fibrosis in Japan
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Ischaemic-heart-disorders in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top